Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.
about
The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumorsNon-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and managementToward rapamycin analog (rapalog)-based precision cancer therapyNew therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.Pancreatic neuroendocrine tumors: the basics, the gray zone, and the target.Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature.Biologics in gastrointestinal and pancreatic neuroendocrine tumorsGenetics of pancreatic neuroendocrine tumors: implications for the clinic.Kmt2a cooperates with menin to suppress tumorigenesis in mouse pancreatic islets.Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future.Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract.Everolimus in the management of metastatic neuroendocrine tumours.An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs).A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies.Vascular hyperpermeability as a hallmark of phacomatoses: is the etiology angiogenesis related to or comparable with mechanisms seen in inflammatory pathways? Part II: angiogenesis- and inflammation-related molecular pathways, tumor-associated macroPhase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518.Sequential treatment in disseminated well- and intermediate-differentiated pancreatic neuroendocrine tumors: Common sense or low rationale?Systemic therapy in incurable gastroenteropancreatic neuroendocrine tumours: a clinical practice guideline.Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy.Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors.Update in the Therapy of Advanced Neuroendocrine Tumors.Pancreatic neuroendocrine tumorsChemotherapy in Pancreatic Cancer: A Systematic Review
P2860
Q26740374-2ED8AFC9-3B36-4319-9CF7-86C0556E879BQ26795597-791ED471-DB3C-4FC0-91F8-30693FF06C67Q26795606-293DFE53-6043-4580-9D52-46E8B5A1B2FCQ30364864-63EE6CEF-299E-4CC0-9F97-133915E5136BQ33672117-0F935788-DDE3-4F5E-ACFD-205C8948FF47Q33737587-C888E845-206C-4E5A-82A6-EDBE2B503623Q33895557-5366086C-4132-4DD7-9398-69970B6F75D4Q36960581-33600CF3-A521-4969-88DA-B5F54764A173Q37544748-13AE31ED-A8F0-46E3-A662-24B295F16B01Q37631597-0C6F3B77-D699-4B36-BBBF-4AC3CF6336C5Q38650864-E7CC3DEB-542B-4078-AB15-5A5642D5B803Q38746782-C0A16A24-410D-485B-AB62-8741C23B5A0AQ38746826-B9B3CDFE-2DD2-48D3-9C22-26BFAC358EDBQ38835123-1CEF0707-ABBF-4A72-BA8D-C1EB09022CAAQ38865046-6000401D-71A2-481F-A785-F3EC39141D20Q39173616-78B297AC-1F66-4059-BDCF-D269FA410266Q39224445-5970CA5A-0585-411B-9779-6AB495D92277Q39848776-0C3037BD-DCD2-46CA-B2EE-C28EE93D1410Q41559421-67E6337A-69E3-48B9-A3F6-6F43F7E858C5Q47099537-5F03D6A6-EF33-46AE-9D8E-50A2F9123D1BQ47393972-A1497B20-DED3-46D8-876C-4BA23234C108Q48295398-21693FF2-1462-4145-923A-17F1B8C64C51Q49970741-363E04AD-903D-41EB-A887-F7B7897D32E4Q56917284-1E374A41-B74A-4DC5-9982-5A677DBFF6EFQ57824846-0E98E845-616A-4720-96B5-920D0931AFFE
P2860
Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Multicenter Phase II Trial of ...... creatic Neuroendocrine Tumors.
@ast
Multicenter Phase II Trial of ...... creatic Neuroendocrine Tumors.
@en
type
label
Multicenter Phase II Trial of ...... creatic Neuroendocrine Tumors.
@ast
Multicenter Phase II Trial of ...... creatic Neuroendocrine Tumors.
@en
prefLabel
Multicenter Phase II Trial of ...... creatic Neuroendocrine Tumors.
@ast
Multicenter Phase II Trial of ...... creatic Neuroendocrine Tumors.
@en
P2093
P2860
P921
P356
P1476
Multicenter Phase II Trial of ...... creatic Neuroendocrine Tumors.
@en
P2093
Andreas Kaubisch
Charles Erlichman
Diane Reidy-Lagunes
Hedy Lee Kindler
Helen Chen
Jonathan Strosberg
Malcolm J Moore
Manisha Shah
Timothy J Hobday
P2860
P304
P356
10.1200/JCO.2014.56.2082
P407
P577
2014-12-08T00:00:00Z